Metal Toxicity & Heart Disease - American Board of Clinical Metal

Download Report

Transcript Metal Toxicity & Heart Disease - American Board of Clinical Metal

Aplicable Disease
World Health Organization 1997

Atherosclerosis and its consequences
(ASPVD, ASCAD, ASCVD) and
Cancer together are responsible for
over 80% of ALL deaths in
industrialized countries
“Cardiovascular Drug Therapy”1996
Metal Toxicity & Heart Disease
Chapter 175 MagnesiumEDTA
chelation Martin Rubin PhD
 EDTA acts as an anti-oxidant, anticoagulant and decalcifies deposits.
 30 infusions of EDTA in a patient 14
years post MI and multi-vessel CABG.
Ultrafast CT scan showed 216
calcified lesions and total calcium
score of 15872. Post chelation: 118
lesions, calcium score 7970

Martin Rubin PhD
Metal Toxicity & Heart Disease

“EDTA chelation has an implicit
advantage in that it can favorably
influence all facets of the
(atherosclerotic) disease
development. Thus it can also provide
an alternative to the combination of
drugs administered to obtain a
multiplicity of therapeutic effects.”
Prof. Martin Rubin
Metal Toxicity & Heart Disease
Metal Toxicity & Heart Disease
Idiopathic Dilated Cardiomyopathy
 Hg – 22,000 x normal
 Sb – 12,000 x normal
 Au – 11 x normal
 Cr – 13 x normal
 Co – 4 x normal
Journal of American College of Cardiology, 1999
Metal Toxicity & PVD
Metal Toxicity & PVD






79 year old woman - Presenting History
1979 NIDDM and hypertension
1992 Mastectomy for breast carcinoma
1993 Increasing PVD
1996 Left hemiplegia CVA
1997 March - Severe pain in left foot at
rest. Hospitalized but refused angiogram
and possible amputation. Started
chelation.
Medications: Minidiab, Adalat, Quinine
sulphate, Warfarin
Became pain-free with improved
circulation after 6 weeks of chelation.
 Discharged from the hospital vascular
clinic after 6 months.
 Maintained on monthly chelations for
4 years

Metal Toxicity & PVD

3 blinded controlled trials
- Olszewer and Carter—10 patients
crossover
- Van Rij—32 patients, slight
improvement, one major outlier
- Guldagger—51% vs. 24% improved




Underpowered, 1/3 dropout
Statistical problems
Patients continued to smoke
Did not follow the standard protocol as
claimed
Metal Toxicity & Vascular Disease
Multi-Centered Trial
 220 patients with documented
vascular disease
 Received chelation with three year
follow-up
 No deaths or MIs, 4 minor strokes
 Symptoms improved
 Chappell, Mitchell, Born, Ventresco,
Hancke, Olszewer, van der Schaar,
Blaha
Metal Toxicity & Vascular Disease
Multi-Centered Trial
 Compared to conventional therapies
-
Expected 31/220 angioplasties, we had 2
Expected 16/220 CABG, we had 6
Expected 15/220 MI’s, we had none
Expected 6/220 deaths, we had none
Of 185 patients with symptoms, 68% had
a complete resolution
Metal Toxicity & MI

Improved myocardial perfusion in
patients with advanced ischemic heart
disease with an integrative
management program including EDTA
metal binding therapy.
Ali M, et al. J Integrative Med.1997;1:7-112
Metal Toxicity & MI

Comparative study of pre- and postchelation myocardial thallium
perfusion scans showed clear,
objective evidence of significant
improvement in myocardial perfusion
in five of six patients in whom such
studies were performed
Metal Toxicity & Heart Disease
EDTA Chelation Therapy in
Myocardial Stunning and Hibernation.
Edwards D, et al. J.Adv.Med
1997;10,4:233-257
 5 Case Reports
 All patients were studied using firstpass radionuclide ventriculography
(RNV) All ejection fractions improved

Metal Toxicity & Heart Disease

Conclusion: EDTA Metal Binding
Therapy clearly and convincingly
reverses the condition of myocardial
hibernation and possibly stunning
Metal Toxicity & ANGINA
Kitchell and Meltzer-- small controlled
trial, and 71% of 38 patients with
disabling angina improved symptoms
and exercise capacity
 Hancke and Flytlie—69% of 253
patients improved EKG and exercise
capacity, 91% of 207 patients on NTG
stopped it, 58/65 on waiting list for
Bypass avoided surgery

Metal Toxicity & ANGINA
Casdorph 16/18 improved ejection
fractions
 Clarke 16/20 patients assymptomatic
after chelation
 Olszewer and Carter 844 patients,
77% marked improvement, 16% good
improvement

Metal Toxicity & Autism
Important Issues of:
 Blood Brain Barrier
 Protein Structure
 Total Mercury Reservoir
Metal Toxicity & Autism
Retrospective Study
 31 patients with diagnosis:
 Autism
 Autism Like Spectrum
 Pervasive Developmental Delay
Metal Toxicity & Autism
Key To Success - Protocol
 Trans Dermal DMPS (TD-DMPS)
 4 : 1 Ratio of GSH : DMPS
 Conjugated with amino acids,
 Delivered in a micro-encapsulated
liposomal phospholipid base
Metal Toxicity & Autism
Retrospective Study
 Baseline
 8 months
 2 months
 10 months
 4 months
 12 months
 6 months
 then 4 months
Metal Toxicity & Autism
Retrospective Study
 All 31 patients tested:
 Urine Metal Toxicity & Essentials
 Hair Metal Toxicity & Essentials
 RBC Metal Toxicity
 Fecal Metal Toxicity
Metal Toxicity & Autism
Retrospective Study
 All 31 patients showed LITTLE or
NO level of mercury on initial
baseline test results